Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Shuying Liu(Capital University), Debasish Tripathy(The University of Texas MD Anderson Cancer Center)
Cited by 24
Related Papers
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
|Journal of Clinical Oncology|2020|113
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
|Research Square|2023|2
Relationship of the expression of myogenic factors in disused rats with bone mass loss and microstructural degeneration
|Osteoporosis and Sarcopenia|2017|1
Vitamin B3 Rescues Mandibular Osteoporosis in Bmi-1–Deficient Mice by Regulating Autophagy
|Research Square|2023|0